CCC publication: Co-primary endpoint of overall survival for tebentafusp (tebe)- induced rash in a phase 3 randomized trial comparing tebe versus investigator's choice (IC) in first-line metastatic uveal melanoma

Citation: Journal of Clinical Oncology. 2021, 39(15) 
Author: Hassel J.C.; Rutkowski P.; Baurain J.-F.; Butler M.O.; Schlaak M.; Sullivan R.; Ochsenreither S.; Dummer R.; Kirkwood J.M.; Joshua A.M.; Sacco J.J.; Shoushtari A.N.; Orloff M.; Carvajal R.D.; Hamid O.; Abdullah S.E.; Holland C.; Goodall H.; Nathan P.; Piperno-Neumann S.